^
    5d
    A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension (clinicaltrials.gov)
    P3, N=378, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Neupogen (filgrastim)
    6d
    RATHL: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=1202, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: May 2023 --> May 2024
    Trial completion • Trial completion date • FDG PET • Metastases
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    8d
    Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=9, Active, not recruiting, University of Colorado, Denver | Trial completion date: Mar 2024 --> Mar 2025
    Trial completion date
    |
    Neupogen (filgrastim)
    13d
    Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=25, Recruiting, M.D. Anderson Cancer Center | N=40 --> 25 | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Enrollment change • Trial completion date • Trial primary completion date • Post-transplantation
    |
    Rituxan (rituximab) • cyclophosphamide • bendamustine • melphalan • fludarabine IV • Neupogen (filgrastim)
    14d
    Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (clinicaltrials.gov)
    P1/2, N=10, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    CD34 (CD34 molecule)
    |
    busulfan • Kepivance (palifermin) • Neupogen (filgrastim) • plerixafor
    19d
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Suspended, University of Washington | Recruiting --> Suspended
    Trial suspension
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 translocation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • daunorubicin • Polivy (polatuzumab vedotin-piiq) • Neupogen (filgrastim)
    19d
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 positive
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    21d
    Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov)
    P3, N=70, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
    Trial completion • Trial completion date • Surgery
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • leucovorin calcium • thiotepa • Neupogen (filgrastim) • methotrexate IV
    26d
    SWOG S1826: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=995, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2032 --> Apr 2025 | Trial primary completion date: Jun 2023 --> Mar 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine • Neulasta (pegfilgrastim) • ABP 206 (nivolumab biosimilar) • Neupogen (filgrastim)
    27d
    Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma (clinicaltrials.gov)
    P2, N=71, Active, not recruiting, The Hospital for Sick Children | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    carboplatin • etoposide IV • vincristine • Neupogen (filgrastim)
    1m
    Stem Cell Transplantation in Crohn's Disease (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • mesna • Neupogen (filgrastim) • methylprednisolone sodium succinate
    1m
    Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (clinicaltrials.gov)
    P1/2, N=10, Enrolling by invitation, National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    CD34 (CD34 molecule)
    |
    busulfan • Kepivance (palifermin) • Neupogen (filgrastim) • plerixafor
    1m
    Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    cisplatin • paclitaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • melphalan • mesna • Neupogen (filgrastim)
    1m
    Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    cytarabine • etoposide IV • idarubicin hydrochloride • Proleukin (aldesleukin) • busulfan • Neupogen (filgrastim)
    1m
    A Case of CD4+ T-Cell Lymphoma With Gamma-Delta Phenotype, Incidentally Manifesting in a Wound Debridement Sample. (PubMed, Am J Dermatopathol)
    The patient was started on mini-CHOP and filgrastim; however, the patient died within 1 month after the diagnosis. This is an interesting case of gamma-delta T-cell lymphoma that was incidentally diagnosed on a chronic wound. In addition, it showed a CD4+, CD8- phenotype that is exceedingly rare for T-cell lymphomas with gamma-delta phenotype.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Neupogen (filgrastim)
    2ms
    St. Jude ELIOT: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, St. Jude Children's Research Hospital
    Trial completion date • Combination therapy
    |
    gemcitabine • cyclophosphamide • prexasertib (ACR-368) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (clinicaltrials.gov)
    P1, N=24, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    paclitaxel • Neupogen (filgrastim)
    2ms
    Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID)
    New P1/2 trial
    |
    CD34 (CD34 molecule)
    |
    busulfan • Kepivance (palifermin) • Neupogen (filgrastim) • plerixafor
    2ms
    SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors (clinicaltrials.gov)
    P1, N=68, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Mar 2025 --> May 2024
    Trial completion date
    |
    PTCH1 (Patched 1)
    |
    PTCH1 mutation
    |
    Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)
    2ms
    Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    topotecan • melphalan • busulfan • Neupogen (filgrastim)
    2ms
    Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery • Metastases
    |
    Avastin (bevacizumab) • cisplatin • docetaxel • etoposide IV • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    2ms
    Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    MLL rearrangement • MLL rearrangement
    |
    Actemra IV (tocilizumab) • cyclosporine • Neupogen (filgrastim)
    2ms
    EMEG-ECDD: Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Centre Georges Francois Leclerc | Trial completion date: Apr 2024 --> Oct 2025 | Trial primary completion date: Apr 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • epirubicin • Neulasta (pegfilgrastim) • Granocyte (lenograstim) • Neupogen (filgrastim)
    2ms
    Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma (clinicaltrials.gov)
    P3, N=107, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • Neupogen (filgrastim)
    3ms
    Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation. (PubMed, Transfusion)
    Initially PLER was investigated in placebo-controlled trials with the granulocyte colony-stimulating factor (G-CSF) filgrastim. This also appears to be the case in patients receiving plerixafor for poor or suboptimal mobilization of CD34+ cells. In practice, PLER is safe and has not been shown to increase tumor cell mobilization.
    Review • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD34 (CD34 molecule)
    |
    Neupogen (filgrastim) • plerixafor
    3ms
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)
    P1, N=40, Recruiting, Stanford University | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
    3ms
    NCI-2011-00344: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    Rituxan (rituximab) • Neupogen (filgrastim) • plerixafor
    3ms
    Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Post-transplantation
    |
    cyclophosphamide • Neupogen (filgrastim)
    3ms
    A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc. | Trial completion date: Dec 2025 --> Aug 2025
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • Neupogen (filgrastim)
    3ms
    NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    ALK fusion • ALK mutation • ALK translocation • ALK amplification
    |
    Lorbrena (lorlatinib) • cyclophosphamide • topotecan • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Gene therapy
    |
    CD34 (CD34 molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim)
    3ms
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • ANPEP (Alanyl Aminopeptidase, Membrane) • MPO (Myeloperoxidase)
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    3ms
    Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor (clinicaltrials.gov)
    P3, N=416, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative • HER-2 expression
    |
    cisplatin • cyclophosphamide • vincristine • Neupogen (filgrastim)
    3ms
    Preventive stRategy for IMMU132-relatED AEs in TNBC - PRIMED (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • Neupogen (filgrastim) • loperamide
    4ms
    Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET (clinicaltrials.gov)
    P3, N=379, Active, not recruiting, Children's Oncology Group | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • vincristine • Neupogen (filgrastim)
    4ms
    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (clinicaltrials.gov)
    P1/2, N=100, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Feb 2024
    Enrollment open • Trial initiation date
    |
    TP53 (Tumor protein P53) • FOXO1 (Forkhead box O1) • MYOD1 (Myogenic Differentiation 1)
    |
    TP53 mutation
    |
    temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)
    4ms
    HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)
    P2, N=140, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion
    |
    cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
    4ms
    SELCLAX: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jun 2024 --> Jul 2025
    Trial completion date • Combination therapy
    |
    Venclexta (venetoclax) • cytarabine • Xpovio (selinexor) • methotrexate • fludarabine IV • Neupogen (filgrastim)
    4ms
    Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov)
    P2, N=153, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Metastases
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • humanised dinutuximab (Hu14.18K322A)
    4ms
    NCI-2018-01186: Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    4ms
    Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET (clinicaltrials.gov)
    P3, N=379, Active, not recruiting, Children's Oncology Group | Trial completion date: Jul 2028 --> Jan 2024
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • vincristine • Neupogen (filgrastim)
    4ms
    CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1, N=120, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)